Cinacalcet , ≥99% , 226256-56-0

CAS NO.：226256-56-0

Empirical Formula: C22H22F3N

Molecular Weight: 357.42

MDL number: MFCD09840270

EINECS: 682-701-7

PRODUCT Properties

• Boiling point: 440.9±45.0 °C(Predicted)
• Density: 1.154±0.06 g/cm3(Predicted)
• storage temp.: Keep in dark place,Sealed in dry,2-8°C
• solubility: Chloroform (Slightly), Methanol (Slightly)
• form: Oil
• pka: 9.19±0.29(Predicted)
• color: Yellow
• InChI: InChI=1/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/s3
• InChIKey: VDHAWDNDOKGFTD-QEIABERDNA-N
• SMILES: [C@H](C1=CC=CC2C=CC=CC1=2)(C)NCCCC1C=CC=C(C(F)(F)F)C=1 |&1:0,r|
• CAS DataBase Reference: 226256-56-0(CAS DataBase Reference)

Description and Uses

Cinacalcet is the first type II calcimimet ic agent approved that improves CaSR sensi Tivity to calcium . When calcium is bound to the CaSR, phospholipase C is act ivated, and the secretion of PTH is inhibited. In the presence of cinacalcet , not only is a drop in PTH levels observed but also a decrease in serum calcium and phosphorous levels.

Cinacalcet is the first calcimimetic drug approved by the United States Food and Drug Administration for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease

Safety

• Symbol(GHS): GHS07,GHS08
• Signal word: Danger
• Hazard statements: H302-H315-H319-H360
• Precautionary statements: P201-P202-P264-P270-P280-P301+P312-P302+P352-P305+P351+P338-P308+P313-P321-P330-P332+P313-P337+P313-P362+P364-P405-P501
• Hazardous Substances Data: 226256-56-0(Hazardous Substances Data)